Health Care & Life Sciences » Biotechnology | Insys Therapeutics Inc.

Insys Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2005
2006
2007
2008
2009
Cash & Short Term Investments
30,262.20
38,587.00
20,781.00
7,298.00
18,992.00
Total Accounts Receivable
1.40
0.00
0.00
0.00
0.00
Inventories
5.70
0.00
0.00
0.00
0.00
Other Current Assets
727.40
627.00
417.00
338.00
310.00
Total Current Assets
30,996.70
39,214.00
21,198.00
7,636.00
19,302.00
Net Property, Plant & Equipment
2,157.50
1,266.00
395.00
366.00
250.00
Total Investments and Advances
0.00
0.00
0.00
15,351.00
650.00
Long-Term Note Receivable
0.00
0.00
0.00
0.00
0.00
Intangible Assets
0.00
0.00
0.00
0.00
0.00
Other Assets
215.70
209.00
659.00
0.00
0.00
Total Assets
33,370.00
40,689.00
22,252.00
23,353.00
20,202.00
ST Debt & Current Portion LT Debt
0.00
30.00
32.00
34.00
13,986.00
Accounts Payable
683.20
5,085.00
1,340.00
222.00
67.00
Other Current Liabilities
8,705.30
4,462.00
2,547.00
3,286.00
2,026.00
Total Current Liabilities
9,388.50
9,577.00
3,919.00
3,542.00
16,079.00
Long-Term Debt
0.00
105.00
74.00
9,241.00
3.00
Deferred Taxes
0.00
0.00
0.00
0.00
0.00
Other Liabilities
2,036.20
2,136.00
6.00
18.00
36.00
Total Liabilities
11,424.70
11,818.00
3,999.00
12,801.00
16,118.00
Common Equity (Total)
21,945.30
28,871.00
18,253.00
10,552.00
4,084.00
Total Shareholders' Equity
21,945.30
28,871.00
18,253.00
10,552.00
4,084.00
Total Equity
21,945.30
28,871.00
18,253.00
10,552.00
4,084.00
Liabilities & Shareholders' Equity
33,370.00
40,689.00
22,252.00
23,353.00
20,202.00
Accumulated Minority Interest
0.00
0.00
0.00
0.00
0.00
Non-Equity Reserves
0.00
0.00
0.00
0.00
0.00
Preferred Stock (Carrying Value)
0.00
0.00
0.00
0.00
0.00

About Insys Therapeutics

View Profile
Address
Suite 970
Lake Bluff 60044
Employees -
Website http://www.neopharm.com
Updated 09/14/2018
NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma.